311 related articles for article (PubMed ID: 31514420)
21. Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center.
Ollech A; Zvulunov A; Pavlovsky L; Hodak E; Ben-Amitai D
J Dermatolog Treat; 2019 Mar; 30(2):152-155. PubMed ID: 29757046
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria.
Pascal C; Maucort-Boulch D; Gilibert S; Bottigioli D; Verdu V; Jaulent C; Hacard F; Bérard F; Nicolas JF; Nosbaum A
J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2339-2345. PubMed ID: 32119144
[TBL] [Abstract][Full Text] [Related]
23. Dupilumab for off-label treatment of moderate to severe childhood atopic dermatitis.
Jorge E; Clark J
Cutis; 2018 Sep; 102(3):201-204. PubMed ID: 30372706
[TBL] [Abstract][Full Text] [Related]
24. Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide.
Fan R; Cohen JM
Yale J Biol Med; 2022 Jun; 95(2):249-255. PubMed ID: 35782480
[TBL] [Abstract][Full Text] [Related]
25. Pustular Psoriasis in a Patient Treated with Dupilumab for Atopic Dermatitis: A Case Report.
Liu L; Chen J; Tang K; Li F; Li S; Ding X
Clin Cosmet Investig Dermatol; 2023; 16():2217-2221. PubMed ID: 37601418
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies for pediatric psoriasis.
Schwartz G; Paller AS
Semin Cutan Med Surg; 2018 Sep; 37(3):167-172. PubMed ID: 30215634
[TBL] [Abstract][Full Text] [Related]
27. Beyond Psoriasis: Novel Uses for Biologic Response Modifiers in Pediatric Dermatology.
Bellodi-Schmidt F; Shah KN
Pediatr Dermatol; 2016; 33(1):18-27. PubMed ID: 26607958
[TBL] [Abstract][Full Text] [Related]
28. Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis.
Maloney NJ; Tegtmeyer K; Zhao J; Worswick S
J Drugs Dermatol; 2019 Oct; 18(10):. PubMed ID: 31603635
[TBL] [Abstract][Full Text] [Related]
29. Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend.
Saikaly SK; Mattes M
Cureus; 2016 Jun; 8(6):e652. PubMed ID: 27462478
[TBL] [Abstract][Full Text] [Related]
30. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre.
Fotiadou C; Lazaridou E; Sotiriou E; Kyrgidis A; Apalla Z; Ioannides D
J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2091-2096. PubMed ID: 27406435
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
33. An update on the topical and oral therapy options for treating pediatric atopic dermatitis.
Glines KR; Stiff KM; Freeze M; Cline A; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2019 Apr; 20(5):621-629. PubMed ID: 30601075
[TBL] [Abstract][Full Text] [Related]
34. "De Novo" Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature.
Trave I; Salvi I; Burlando M; Cozzani E; Parodi A
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834935
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
36. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
37. An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis.
Brezinski EA; Armstrong AW
Curr Med Chem; 2015; 22(16):1930-42. PubMed ID: 25921645
[TBL] [Abstract][Full Text] [Related]
38. Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report.
Kim HS; Yeung J
SAGE Open Med Case Rep; 2020; 8():2050313X20940458. PubMed ID: 32699634
[TBL] [Abstract][Full Text] [Related]
39. The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders.
Nguyen QD; Starling CT; Hebert AA
Paediatr Drugs; 2020 Jun; 22(3):311-319. PubMed ID: 32350817
[TBL] [Abstract][Full Text] [Related]
40. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
